HeartCore Signs 13th Go IPO Contract
NEW YORK and TOKYO, March 18, 2024 (GLOBE NEWSWIRE) -- HeartCore Enterprises, Inc. (Nasdaq: HTCR) (“HeartCore” or the “Company”), a leading enterprise software and consulting services company based in Tokyo, announced that it has signed an agreement (“Consulting Agreement”) with PharmaBio Corporation (“PharmaBio”) for its 13th Go IPO consulting service win.
- NEW YORK and TOKYO, March 18, 2024 (GLOBE NEWSWIRE) -- HeartCore Enterprises, Inc. (Nasdaq: HTCR) (“HeartCore” or the “Company”), a leading enterprise software and consulting services company based in Tokyo, announced that it has signed an agreement (“Consulting Agreement”) with PharmaBio Corporation (“PharmaBio”) for its 13th Go IPO consulting service win.
- As compensation for its services, HeartCore expects to generate from PharmaBio an aggregate of $500,000 in initial fees and $300,000 in success fees.
- In addition, HeartCore has received a warrant to acquire 3% of PharmaBio’s common stock, on a fully diluted basis.
- “I am pleased to announce our 13th Go IPO contract win and our second contract for 2024,” said HeartCore CEO Sumitaka Kanno Yamamoto.